12 December 2019

ARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced the successful closure of a CHF 8.8M seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in 2021. The funding will be used to advance the company’s healthtech platform into a large multicentre clinical study aiming to further validate the value of ARTIDIS in diagnosing breast and lung cancer, as well as for personalizing and optimizing cancer treatment.

VISCHER AG acted as counsel to ARTIDIS. The team was led by Matthias Staehelin (Partner, Corporate) and supported by Fiona Gao and Luzius Zumstein (Associates, Corporate).

Press release

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.